CCR6 is required for epidermal trafficking of γδ-T cells in an IL-23-Induced model of psoriasiform dermatitis

Journal of Investigative Dermatology

Volumn 133, Issue 1, 2013, Pages 164-171

  Mabuchi, Tomotaka ^a   Singh, Tej Pratap ^b   Takekoshi, Tomonori ^a   Jia, Guang Fu ^a   Wu, Xuesong ^a   Kao, Mandy C ^a   Weiss, Ido ^b   Farber, Joshua M ^a   Hwang, Sam T ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR6; INTERLEUKIN 23; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL MIGRATION; CONTROLLED STUDY; DERMIS; EAR; EPIDERMIS; GAMMA DELTA T LYMPHOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; UPREGULATION;

EID: 84872172469     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2012.260     Document Type: Article

References (32)

1. Cai Y, Shen X, Ding C et al. (2011) Pivotal role of dermal IL-17-producing gammadelta T cells in skin inflammation. Immunity 35:596-6100
2. Caruso R, Botti E, Sarra M et al. (2009) Involvement of interleukin-21 in the epidermal hyperplasia of psoriasis. Nat Med 15:1013-55
3. Chan JR, Blumenschein W, Murphy E et al. (2006) IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 203:2577-877
4. Cua DJ, Tato CM (2010) Innate IL-17-producing cells: The sentinels of the immune system. Nat Rev Immunol 10:479-899
5. Elhofy A, Depaolo RW, Lira SA et al. (2009) Mice deficient for CCR66 fail to control chronic experimental autoimmune encephalomyelitis. J Neuroimmunol 213:91-99
6. Fitch E, Harper E, Skorcheva I et al. (2007) Pathophysiology of psoriasis: Recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 9: 461-77
7. Girardi M (2006) Immunosurveillance and immunoregulation by gammadelta T cells. J Invest Dermatol 126:25-311
8. Gray EE, Suzuki K, Cyster JG (2011) Cutting edge: Identification of a motile IL- 17-producing {gamma}{delta} T cell population in the dermis. J Immunol 186:6091-55
9. Haas JD, Gonzalez FH, Schmitz S et al. (2009) CCR6 and NK1.1 distinguish between IL-17A and IFN-gamma-producing gammadelta effector T cells. Eur J Immunol 39:3488-977
10. Harper EG, Guo C, Rizzo H et al. (2009) Th17 cytokines stimulate CCL200 expression in keratinocytes in vitro and in vivo: Implications for psoriasis pathogenesis. J Invest Dermatol 129:2175-833
11. Hedrick MN, Lonsdorf AS, Hwang ST et al. (2010) CCR6 as a possible therapeutic target in psoriasis. Expert Opin Ther Targets 14:911-222
12. Hedrick MN, Lonsdorf AS, Shirakawa AK et al. (2009) CCR6 is required for IL-23-induced psoriasis-like inflammation in mice. J Clin Invest 119:2317-299
13. Hirota K, Yoshitomi H, Hashimoto M et al. (2007) Preferential recruitment of CCR6-expressing Th17 cells to inflamed joints via CCL20 in rheumatoid arthritis and its animal model. J Exp Med 204:2803-122
14. Homey B, Dieu-Nosjean M, Wiesenborn A et al. (2000) Up-regulation of macrophage inflammatory protein-3a/CCL20 and CC chemokine receptor 6 in psoriasis. J Immunol 164:6621-322
15. Kagami S, Rizzo HL, Lee JJ et al. (2010) Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 130:1373-833
16. Laggner U, Di Meglio P, Perera GK et al. (2011) Identification of a novel proinflammatory human skin-homing V{gamma}9V{delta}2 T cell subset with a potential role in psoriasis. J Immunol 187:2783-933
17. Lazarova Z, Yee C, Darling T et al. (1996) Passive transfer of anti-laminin 55 antibodies induces subepidermal blisters in neonatal mice. J Clin Invest 98:1509-188
18. Leonardi CL, Kimball AB, Papp KA et al. (2008) Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). Lancet 371:1665-744
19. Liston A, Kohler RE, Townley S et al. (2009) Inhibition of CCR6 function reduces the severity of experimental autoimmune encephalomyelitis via effects on the priming phase of the immune response. J Immunol 182:3121-300
20. Mabuchi T, Chang TW, Quinter S et al. (2012) Chemokine receptors in the pathogenesis and therapy of psoriasis. J Dermatol Sci 65:4-111
21. Mabuchi T, Takekoshi T, Hwang ST (2011) Epidermal CCR6+ gammadelta T cells are major producers of IL-22 and IL-17 in a murine model of psoriasiform dermatitis. J Immunol 187:5026-311
22. Murakami T, Cardones AR, Finkelstein SE et al. (2003) Immune evasion by murine melanoma mediated through CC chemokine receptor-10. J Exp Med 198:1337-477
23. Nograles KE, Davidovici B, Krueger JG (2010) New insights in the immunologic basis of psoriasis. Semin Cutan Med Surg 29:3-99
24. Rizzo HL, Kagami S, Phillips KG et al. (2011) IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol 186:1495-5022
25. Salgado CG, Nakamura K, SugayaM et al. (1999) Differential effects of cytokines and immunosuppressive drugs on CD40, B7-1, and B7-2 expression on purified epidermal langerhans cells1. J Invest Dermatol 113:1021-77
26. Schutyser E, Struyf S, Van Damme J (2003) The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 14:409-266
27. Sutton CE, Lalor SJ, Sweeney CM et al. (2009) Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th177 responses and autoimmunity. Immunity 31:331-411
28. Szabo SK, Hammerberg C, Yoshida Y et al. (1998) Identification and quantitation of interferon-gamma producing T cells in psoriatic lesions: Localization to both CD4+ and CD8+ subsets. J Invest Dermatol 111:1072-88
29. Van Belle AB, de Heusch M, Lemaire MM et al. (2012) IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice. J Immunol 188:462-99
30. Villares R, Cadenas V, Lozano M et al. (2009) CCR6 regulates EAE pathogenesis by controlling regulatory CD4+ T-cell recruitment to target tissues. Eur J Immunol 39:1671-811
31. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J et al. (2009) Effective treatment of psoriasis with etanercept is linked to suppression of IL-177 signaling, not immediate response TNF genes. J Allergy Clin Immunol 124:1022-10.e1-3955
32. Zheng Y, Danilenko DM, Valdez P et al. (2007) Interleukin-22, a T(H)177 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445:648-511